Date: October 30, 2026

Financial Performance Overview

Lyka Labs Limited announced its unaudited financial results for Q2 FY27 (quarter ended September 30, 2026) and H1 FY27 (half year ended September 30, 2026), showing significant improvement across all key metrics.

Quarterly Performance (Q2 FY27)

Standalone Results:

  • Revenue from Operations: ₹4,419.95 lakhs, up 34.06% from ₹3,297.03 lakhs in Q2 FY26
  • EBITDA: ₹419.31 lakhs, showing 326.02% improvement from negative ₹185.52 lakhs in Q2 FY26
  • EBITDA Margin: 9.49% compared to negative 5.63% in Q2 FY26
  • Finance Cost: ₹102.18 lakhs, increased from ₹78.58 lakhs in Q2 FY26
  • Profit Before Tax: ₹111.76 lakhs, showing 123.33% improvement from negative ₹479.05 lakhs in Q2 FY26
  • Net Profit After Tax: ₹131.50 lakhs, showing 136.32% improvement from negative ₹362.07 lakhs in Q2 FY26

Consolidated Results:

  • Revenue from Operations: ₹4,419.95 lakhs, up 20.56% from ₹3,666.05 lakhs in Q2 FY26
  • EBITDA: ₹414.21 lakhs, showing 386.31% improvement from negative ₹144.67 lakhs in Q2 FY26
  • EBITDA Margin: 9.37% compared to negative 3.95% in Q2 FY26
  • Finance Cost: ₹102.18 lakhs, increased from ₹78.87 lakhs in Q2 FY26
  • Profit Before Tax: ₹106.66 lakhs, showing 124.32% improvement from negative ₹438.49 lakhs in Q2 FY26
  • Net Profit After Tax: ₹127.11 lakhs, showing 139.54% improvement from negative ₹321.44 lakhs in Q2 FY26

Half-Yearly Performance (H1 FY27)

Standalone Results:

  • Revenue from Operations: ₹8,650.89 lakhs, up 39.20% from ₹6,214.67 lakhs in H1 FY26
  • EBITDA: ₹920.44 lakhs, showing 304.50% improvement from ₹227.55 lakhs in H1 FY26
  • EBITDA Margin: 10.64% compared to 3.66% in H1 FY26
  • Finance Cost: ₹203.00 lakhs, increased from ₹163.72 lakhs in H1 FY26
  • Profit Before Tax: ₹311.10 lakhs, showing 185.87% improvement from negative ₹362.31 lakhs in H1 FY26
  • Net Profit After Tax: ₹341.53 lakhs, showing 221.55% improvement from negative ₹280.99 lakhs in H1 FY26

Consolidated Results:

  • Revenue from Operations: ₹8,650.89 lakhs, up 24.14% from ₹6,968.59 lakhs in H1 FY26
  • EBITDA: ₹910.80 lakhs, showing 217.27% improvement from ₹287.07 lakhs in H1 FY26
  • EBITDA Margin: 10.53% compared to 4.12% in H1 FY26
  • Finance Cost: ₹203.00 lakhs, increased from ₹164.25 lakhs in H1 FY26
  • Profit Before Tax: ₹301.46 lakhs, showing 199.39% improvement from negative ₹303.31 lakhs in H1 FY26
  • Net Profit After Tax: ₹331.77 lakhs, showing 249.57% improvement from negative ₹221.81 lakhs in H1 FY26

Revenue Analysis

Domestic Revenue Performance:

  • Q2 FY27 Domestic Revenue: ₹2,948.90 lakhs, up 12.89% year-over-year
  • H1 FY27 Domestic Revenue: ₹5,601.01 lakhs, up 14.30% year-over-year

Domestic Segment Breakdown:

  • Branded Formulation: Q2 FY27 ₹521.43 lakhs (3.18% growth), H1 FY27 ₹1,259.10 lakhs (31.16% growth)
  • Branded Veterinary: Q2 FY27 ₹824.82 lakhs (48.03% growth), H1 FY27 ₹1,412.17 lakhs (65.34% growth)
  • P2P: Q2 FY27 ₹1,602.65 lakhs (3.43% growth), H1 FY27 ₹2,929.75 lakhs (-5.07% decline)

Export Revenue Performance:

  • Q2 FY27 Export Revenue: ₹1,415.49 lakhs, up 51.89% year-over-year
  • H1 FY27 Export Revenue: ₹2,898.92 lakhs, up 59.74% year-over-year

Export Segment Breakdown:

  • Branded Formulation: Q2 FY27 ₹1,415.49 lakhs (51.89% growth), H1 FY27 ₹2,898.92 lakhs (59.74% growth)

Other Operating Income:

  • Q2 FY27: ₹55.55 lakhs, down 54.47% year-over-year
  • H1 FY27: ₹150.96 lakhs, down 40.46% year-over-year

Company Business Description

Lyka Labs Limited is engaged in the manufacturing and marketing of finished pharmaceutical formulations for human and animal healthcare across a wide range of therapeutic segments, catering to both domestic and international markets.